logo of the EU drugs agency

You are viewing archived content

Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the EMCDDA.

Table TDI-23. Polydrug use among all clients entering outpatient treatment, for countries supplying data for 2006: opioids, cocaine, cannabis or other stimulants as primary drug type combined with a secondary drug type [see all tables in this series...]

Part (i) Percentage distribution of secondary drug by primary drug for the EU overall

Primary drug Secondary drug
Number of clients OpioidsCocaineOther stimulantsHypnotics/sedativesHallucinogensVolatile substancesCannabisAlcoholOther substances


 Countries included: BG, CZ, DK, DE, IE, EL, ES, FR, IT, CY, LV, LU, MT, NL, AT, SK, FI, SE, UK. 

 Data on secondary drug use are only collected among all treatment clients and not separately for new treatment clients. 

 ‘Opioids’ include: heroin, methadone, other opioids; ‘Cocaine’ includes: cocaine HCl, crack cocaine; ‘Stimulants’ include: amphetamines, MDMA and derivates, other stimulants: ‘Cannabis’ can include herb or resin. For each client up to four secondary drugs can be reported. 

 A number of the clients report using the same drug both as primary and secondary drug, particularly for cannabis. Clients may report using different sub-types of the same substance, as defined in the TDI protocol for the drugs categories. The greater part of clients using cannabis both as primary and secondary drug comes from Germany. 

 See also 'General notes for interpreting data’ on the Explanatory notes and help page


 Reitox national reports 2007.  

(see the help page for information about formats etc.)

Page last updated: Monday, 14 July 2008